Allen Duplantier, PhD

Principal investigator

Dr. Allen Duplantier is a medicinal chemist with 20 years of industry and 8 years of government experience in drug discovery and development.  He has worked in all stages of early drug development including hit-to-lead, lead optimization, candidate selection and IND submission, and has a proven track record in delivering clinical candidates in multiple therapeutic areas. He has been a project leader across chemistry, biology, DMPK, toxicology and pharmaceutical sciences, and has a strong capability of designing drugs that provide adequate unbound drug levels in target tissue. He has years of direct interaction and collaboration with funding agencies, military labs, big pharma and numerous small biotechs and universities. He is an effective science and technology manager of large and broad portfolio of projects and a successful manager of external chemistry, ADME and pharmacokinetic resources through CROs. He is a multidisciplinary collaborator and mentor.

Dr. Duplantier received a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology, and a B.S. in Chemistry from the University of New Orleans.

More team members

Andrew Fradkin, JD
General Counsel
Walter Greenblatt, MBA
Chief Financial Officer
Mike McGinnis, MS, MBA
Head of Government Relations
Anne Moscona, MD
Ruth Karron, MD
Matteo Porotto, PhD
Elma Hawkins, PhD, MBA
Chairwoman of the Board
Fred Hayden, MD
Joan Fusco, PhD
Chief Development Officer
Tom Monath, MD
Chief Medical Officer
Sean Whelan, PhD
Daniel Graifman, MBA